Back to the articles
MEDILAC-S: A PROMISING ADJUVANT IN IBS MANAGEMENT
A comprehensive systematic review and meta-analysis have underscored the potential of Medilac-S, a combination of Bacillus subtilis R0179 and Enterococcus faecium R0026; non-commercially known as IBacilluS+, as an effective adjuvant to conventional irritable bowel syndrome (IBS) therapies.
The newly published study, titled “Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis,” synthesizes findings from over 33 clinical trials involving 3,174 adults diagnosed with different IBS subtypes. Medilac-S as an adjuvant demonstrated a remarkable 21% increase in treatment efficacy (p < 0.0001). Importantly, this improvement was consistent across all IBS subtypes. When studied alone, Medilac-S also performed comparably to conventional treatments, as evidenced by a subset of 17 studies. Furthermore, these findings reinforce the safety and effectiveness of Medilac-S as an adjuvant in IBS management.
“Our formula IBacilluS+ is a probiotic combination for serious gut conditions, documented in 120 clinical studies, involving more than 10,000 participants, across various medical contexts, ranging from ulcerative colitis to acute gastritis, Small Intestinal Bacterial Overgrowth (SIBO), Helicobacter pylori, Antibiotic-associated diarrhea, and IBS. This specific review reaffirms the substantial gut health benefits associated with our probiotic bacteria formula for IBS management. The clinical evidence demonstrates that IBacilluS+ can minimize recurrent symptoms and maximize quality of life and reinforces the clinical findings made over the last decade”, summarizes Sylvie Binda, Vice President of Research and Development at Lallemand Health Solutions.
About Lallemand Health Solutions – Leading Probiotics Forward
Lallemand Health Solutions is a pioneering company recognized as a vertically integrated global leader in manufacturing probiotic yeast and bacteria-based formulas. These formulas are designed for human health supplements, food applications, and nutricosmetics. With manufacturing processes adhering to the highest quality standards, including Good Manufacturing Practices, and an ambitious research program, Lallemand Health Solutions’ probiotics are documented to deliver benefits in gut health, immune support, mental well-being, women’s health, skin care, oral health, and metabolic health. Currently, over 600 probiotic formulas are marketed in over 60 countries across five continents.
Marilou Luneau, Communications Manager
Lallemand Health Solutions